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Long-term effects of calcium carbonate and 2.5 mEq/liter calcium
dialysate on mineral metabolism. Many investigators have shown that
calcium carbonate (CaCO3) is an effective phosphate binder which also
prevents the potential disabling effects of aluminum (Al) accumulation.
However, hypercalcemia may develop in a substantial numbers of
patients. Thus, to control serum phosphate (P04) and prevent hyper-
calcemia, we performed studies in 21 patients on maintenance hemodi-
alysis in which, in addition to the oral administration of CaCO3, the
concentration of calcium (Ca) in the dialysate was reduced from 3.25 to
2.5 mEq/liter. The studies were divided in three periods: I. control, on
Al-binders (one month); II. no Al-binders (one month); III. CaCO3
(seven months). Blood was obtained three times/week before dialysis
for the first five months of the study and once a week for the remaining
four months. During the control period, the mean serum calcium was
8.86 0.08 mg/dl. The value decreased to 8.65 0.07 mg/dl when
phosphate binders containing aluminum were discontinued, and in-
creased to 9.19 0.07 mg/dl (P < 0.001 compared to period II) during
oral supplementation with calcium carbonate. The mean serum phos-
phorus was 5.03 0.07 mg/dl during the control period, and increased
to 7,29 0.91 mg/dl (P < 0.001) after phosphate binders were
discontinued. It decreased to 4.95 0.06 mg/dl (P < 0.001) with the
administration of calcium carbonate. During CaCO3 administration,
serum Al decreased from 64.2 8.5 to 37.1 3.6and 25.1 3.0 sg/liter(P < 0.001) at three and seven months, respectively. Serum parathyroid
hormone (PTH) decreased by 20%. In summary, lowering dialysate Ca
to 2.5 mEq/liter allowed the long-term administration of large doses of
CaCO3 (10.5 g/day). This corrected the hyperphosphatemia without the
development of hypercalcemia or worsening of the secondary hyper-
parathyroidism. Al levels returned toward normal. Thus, by utilizing
this maneuver aluminum binders may be unnecessary in the majority of
patients on maintenance hemodialysis.
Hyperphosphatemia is a universal finding in patients with
advanced renal insufficiency. Phosphate retention plays a crit-
ical role in the development of secondary hyperparathyroidism,
metastatic calcifications and pruritus [1]. Although controversy
exists [1] regarding the exact mechanism by which phosphate
retention produces secondary hyperparathyroidism, it is clear
that if hyperphosphatemia can be avoided, secondary hyper-
parathyroidism can be prevented [2—5]. In the past 25 years
physicians have effectively controlled serum phosphorus in
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most uremic patients by the use of phosphate binders contain-
ing aluminum. However, numerous investigators have demon-
strated a deleterious effect of aluminum accumulation in dialy-
sis patients [6—16]. Thus, alternative methods to control serum
phosphate have been developed. Among them, the use of
CaCO3 is by far the most common [17—23]. The dose of calcium
carbonate prescribed to control serum phosphate varies greatly
from patient to patient and directly correlates with the amount
of phosphorus ingested in the diet [221. Approximately 30% of
patients ingest a diet high in phosphorus content and, therefore,
require a large intake of calcium carbonate. In this group of
patients hypercalcemia often precludes a further increment in
CaCO3. Thus, phosphate binders containing aluminum are still
required to prevent the development of hyperphosphatemia
[22]. Moreover, a large number of patients receive 1 ,25(OH)2D3
for the treatment of secondary hyperparathyroidism. The com-
bination of a highly potent metabolite of vitamin D and large
doses of CaCO3 may potentially increase the risk of hypercal-
cemia and metastatic calcification. In this country, most pa-
tients are dialyzed with a dialysate containing 3.25 to 3.5
mEq!liter of calcium. Several investigators have demonstrated
[24—26] that a positive calcium balance can be induced with a
calcium concentration of 3.5 mEqlliter in the dialysate. If in
addition the patient ingests large amounts of CaCO3, there may
be a risk of developing metastatic calcification.
Thus, in an attempt to circumvent the development of hyper-
calcemia and potentially decrease the risk of metastatic calcifi-
cations in patients receiving large doses of CaCO3, we decided
to decrease the amount of calcium in the dialysate from 3.25 to
2.5 mEq/liter. In this study, we investigated the usefulness of
long-term administration of CaCO3 in conjunction with a low-
ered concentration of calcium in the dialysate in the treatment
of hyperphosphatemia in 21 maintenance hemodialysis patients.
Methods
We studied 21 patients (8 men and 13 women) who received
long-term hemodialysis and who were 33 to 64 years old. The
residual creatinine clearance in all patients was less than 1
mllmin. The causes underlying renal insufficiency were diabetes
(N = 3), nephrosclerosis (N = 11), chronic glomerulonephritis
(N = 3), obstructive uropathy (N = 2), and pyelonephritis (N =
1). In one patient the diagnosis was unknown. The 21 patients
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Table 1. Dietary phosphorus intake
Breakfast
Amount %
mg Total
Lunch
Amount %
mg Total
Dinner
Amount %
mg Total
Total
amount
mg
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
365 26
235 23
240 33
81 12
200 18
50 6
435 32
199 29
230 28
240 34
400 34
170 22
250 22
370 36
410 38
425 45
270 32
330 39
290 27
245 27
210 28
305 22
403 39
310 43
297 46
444 41
389 50
488 35
193 28
150 19
190 27
350 30
330 42
370 33
245 24
330 31
— —
280 33
— —
385 35
270 30
150 20
725
388
175
274
442
338
454
296
430
270
420
280
510
405
330
510
290
520
410
385
380
52
38
24
42
41
44
33
43
53
39
36
36
45
40
31
55
35
61
38
43
51
1395
1026
725
652
1086
777
1377
688
810
700
1170
780
1130
1020
1070
935
840
850
1085
900
740
Mean
SEM
268.8 28.3
22.5 1.9
280.0 29.9
29,0 2.9
392.00
25.2
41.8
1.9
940.8
46.2
were routinely dialyzed on Fresenius 2008 C dialysis machines,
utilizing blood flows of 400 ml/min and bicarbonate dialysate
flows of 500 mI/mm. They received three hours of dialysis three
times a week. The dialyzers were Clirans TAF 10 and 12. The
concentration of calcium in the dialysate was 2.5 mEq/liter and
the aluminum content was less than 10 sg/1iter.
The criteria for including patients in our study were compli-
ance with the medication regimen, dialysis at our unit for at
least two years, and good control of the serum phosphorus level
(4.0 to 5.5 mg/dl). No patient received supplementation with
vitamin D. The patients were interviewed by three dietitians
during each test period of the study to allow assessment of the
amount of calcium and phosphorus in the diet. The method for
gathering the nutritional data combined dietary histories and
food diaries. No attempt was made to alter the patients' diets,
In addition, the dietitians did periodic assessments of the
amounts of phosphorus and calcium ingested at each meal.
These quantities were calculated according to the method
described by Adams [27]. Written consent was obtained from
all patients, and the studies were approved by the Human
Research Committee of Washington University.
The study was divided into three periods. In all the periods
the concentration of calcium in the dialysate was 2.5mEq/liter
During the control period (one month), the patients continued
to take the previously prescribed amount of phosphate binders
containing Al. During the second period (one month), all
phosphate binders containing aluminum were discontinued and
hyperphosphatemia was allowed to develop. At the beginning
of the third period of the study (seven months), 1 to 2 g of
calcium carbonate was initially prescribed to be taken two or
three times a day with meals. This amount was gradually
increased during the next two months of the study until the
target pre-dialysis phosphorus levels of 4.5 to 5.5 mg/dl were
Table 2. Dietary calcium intake
Breakfast
Amount %
mg Total
Lunch
Amount %
mg Total
Dinner
Amount %
mg Total
Total
amount
mg
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
100
149
163
111
125
78
231
80
102
66
108
83
140
262
104
174
121
130
88
93
58
29
39
44
34
26
23
45
37
30
26
25
16
28
57
34
36
35
33
23
36
18
80 23
100 26
108 29
96 29
112 24
136 41
136 27
52 24
128 38
80 31
198 46
342 64
212 42
— —
77 25
165 34
92 27
— —
138 36
62 24
98 30
165
132
103
120
238
121
144
86
106
108
122
107
148
200
124
141
132
267
160
101
166
48
35
28
37
50
36
28
39
32
43
29
20
30
43
41
29
38
67
41
39
52
345
381
374
327
475
335
511
218
336
254
428
532
500
462
305
480
345
397
386
256
322
Mean
SEM
122.2
10.9
32.1
2.0
114.9 29.6
16.6 3.1
142.4
9.7
38.3
2.2
379.5
19.0
obtained. Serum levels of calcium and phosphorus were deter-
mined before dialysis three times a week during the first five
months of the study and once a week for the remaining four
months. The data for each patient represent the mean values
obtained during each study period. Group data represent the
means of the individual mean values. Parathyroid hormone and
Al were determined in each study period.
The total concentration of calcium was determined by atomic
absorption spectroscopy (Perkin-Elmer, Norwalk, Connecti-
cut, USA, model 503). Ionized calcium was determined using
an Orion electrode (Orion Biomedical, Cambridge, Massachu-
setts, USA). Phosphorus was measured by the Technicon
AutoAnalyzer (Technicon Instruments, Tarrytown, New York,
USA). Serum levels of immunoreactive parathyroid hormone
were measured with antibody CH9, which recognizes the intact,
mid region, and C-terminal portion of the parathyroid hormone
molecule. The method used in the radioimmunoassay for para-
thyroid hormone has been described previously [28]. The Al
concentration was determined by flameless atomic-absorption
spectrometry (Perkin-Elmer, graphite furnace model HG8-400).
The results are expressed as means SE. The statistical
analysis used Student's 1-test for paired data and analysis of
variance when appropriate.
Results
Preliminary studies were performed in all 21 patients to
determine if a dialysate calcium of 2.5 mEq/liter would greatly
affect serum calcium. Mean total serum calcium was 9.45
0.27 mg/dl before and 9.22 0.14 mg/dl after dialysis (P = NS).
A similar pattern was observed for ionized calcium, 4.47 0.16
mg/dl and 4.43 0.07 mg/dl (P = NS). Table 1 illustrates the
amount of phosphorus ingested in the diet. The mean was 940
46 mg/day. However, a large range of 650 to 1400 mg was noted.
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Moreover, the amount of phosphorus ingested was not equally
distributed among the three meals. The larger amount, 42%,
was ingested at dinner with a range of 175 to 725 mg. The
amount of calcium ingested in the diet is shown in Table 2. The
mean was 379 19 mg/day with a range of 220 to 530 mg/day.
Because of the large variability in the daily dietary intake of
phosphorus the total amount of CaCO3 taken by our patients
ranged from 3.5 to 18 g per day (mean 10.5 g/day). A close
correlation was observed between the amount of phosphorus in
the diet and the amount of CaCO3 required to control the serum
phosphorus levels (P <0.001; Fig. 1).
During the control period, the mean serum calcium was 8.86
0.08 mg/dl (N = 252). The value decreased slightly to 8.65
0.07 mg/dl (N = 252) when phosphate binders containing Al
were discontinued. It increased to 9.19 0.07 mg/dl (N = 1092,
P < 0.001) during oral supplementation with calcium carbonate.
The mean serum phosphorus was 5.03 0.07 mg/dl (N = 252)
during the control period. The value increased to 7.29 0.91
mg/dl (N = 252, P < 0.001) after phosphate binders were
discontinued and decreased to 4.95 0.06 mg/dl (N = 1092, P
< 0.001 compared to period II) after the administration of
CaCO3. The calcium phosphorus product was similar during Al
(OH)3 and CaCO3 administration (43.5 vs. 45.4, respectively; P
= NS). The average daily dose of aluminum hydroxide per
patient was 5.1 g (range 2.0 to 13.5). By the end of the study,
none of the patients required aluminum hydroxide. Figure 2
summarizes the changes in serum calcium and phosphorus in
each period (N = 1596).
Serum aluminum levels averaged 64.2 8.5 pg/liter during
control phase. Aluminum levels were 37.1 3.6 g/1iter and 25
3.03 pg/liter, three and seven months, respectively, alter
stopping all the Al-containing phosphate binders (P <0.001).
As serum aluminum varied greatly among subjects (13 to 201
pg/liter), results obtained in those patients which demonstrated
serum aluminum levels greater than 75 tg/liter were evaluated.
Figure 3 depicts the results obtained in eight patients during
control and after three and seven months on calcium carbonate.
Serum aluminum gradually decreased from 100 8.4 pg/liter to
55 2.2 /Lg/liter and then to 37 2.6 tg/liter, respectively (P <
0.001).
Since the concentration of calcium in the dialysate was
decreased from 3.5 to 2.5 mEq/liter, secondary hyperparathy-
roidism could potentially be aggravated. Figure 4 shows that
after three and seven months of treatment with calcium carbon-
ate and 2.5 mEq/liter calcium dialysate, the levels of i-PTH did
not increase. PTH decreased by 20% although this was not
statistically significant.
Discussion
Two decades ago, Clarkson and collaborators [17] demon-
strated that a high dietary intake of calcium carbonate in
patients with chronic renal failure decreased the absorption of
phosphorus by the gastrointestinal tract. Subsequently, many
investigators have shown that CaCO3 is an effective phosphate
binder [18—231. However, the administration of CaCO3 is not
completely free of side effects. Transient episodes of hypercal-
cemia have been frequently observed by several investigators
[18, 20—23]. Moreover, the long-term effects of large adminis-
tration of CaCO3 have not been fully evaluated. Ideally, the
administration of calcium carbonate or other calcium salts
should control serum phosphorus without inducing the devel-
opment of hypercalcemia. In the United States, most of the
patients are dialyzed with a dialysate containing 3.25 to 3.5
mEq/liter of calcium. Since positive calcium balance can be
induced with a concentration of calcium in the dialysate of 3.5
mEq/liter, the administration of large amounts of calcium
carbonate could potentially increase the risk of metastatic
calcifications. Recently, physicians have attempted to decrease
the incidence of hypercalcemic episodes by decreasing the
amount of calcium in the dialysate. Mactier and collaborators
studied the effect of CaCO3 and concomitant reduction in the
amount of calcium in the dialysate to prevent the development
of hypercalcemia [29]. In a group of 41 patients on hemodialy-
sis, eleven patients developed hypercalcemia on calcium car-
bonate. They reduced the dialysate calcium to a mean of 2.1
mEq/liter. This maneuver allowed continuation of calcium
carbonate and maintained predialysis serum calcium and phos-
phorus in the normal range. Similar results were obtained by
Sawyer and collaborators [30]. They studied a group of 15
patients on maintenance hemodialysis. These investigators in-
creased the amount of calcium carbonate in a gradual manner
with a combined stepwise reduction in dialysate calcium as
dictated by serum calcium concentrations. These investigators
obtained a significative control of serum phosphorus and main-
tained serum calcium in the normal range. In addition, they
observed an improvement in the degree of secondary hyper-
parathyroidism. In the current study we evaluated the effect of
long-term administration of CaCO3 in conjunction with a 2.5
mEq/liter calcium concentration in the dialysate in the treat-
S
...
16
12
8
.
.3)
Di
CD
C
C,00
CD0
S
.
.
••
4
0
0.6 0.8 1.0 1.2
Dietary phosphorus, g/day
1.4
Fig. 1. The relationship between phosphorus ingestion and CaCO3
administration.
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Fig. 3. The effect of discontinuing Al (OH)3 on serum aluminum (P <
0.001).
ment of hyperphosphatemia. It is clear that calcium carbonate
serves as an effective phosphate binder in this study. Moreover,
the development of hypercalcemia was greatly minimized by
the concomitant reduction of calcium in the dialysate from 3.5
to 2.5 mEq/liter. There were five episodes of mild hypercalce-
mia in patients in our study who ingested large amounts of
phosphorus and in whom correction of hyperphosphatemia was
attempted by administration of very large quantities (greater
than 13 grams) of calcium carbonate. As soon as the serum
calcium concentration reached 11.5 mg/dl in these patients, the
calcium carbonate was discontinued. After two to four days,
the serum calcium levels returned to normal. In our previous
study with calcium carbonate [22], six of the twenty patients
continued to need oral aluminum hydroxide to achieve satisfac-
tory control of hyperphosphatemia. In the current study, we
were able to control serum phosphorus in all 21 patients with
calcium carbonate. None of the patients required aluminum
hydroxide. We also observed a remarkable decrease in the
levels of serum aluminum during the administration of calcium
carbonate as has been previously reported [21—23, 311. Baseline
serum aluminum decreased from 64.2 8.5 pg/liter to 25.0
3.03 pg/liter after seven months on calcium carbonate. Al-
Control
0/C
Al u ml num Calcium carbonate
20
2001
100
Fig. 2. The effect of CaCO3 and 2.5 mEqIL
Ca dialysate on serum Ca and phosphorus in
21 patients on hemodialysis. Period I, Control
3 4 5 6 7 8 9 on Al binders (one month), Period II, no
aluminum hydroxide (one month), Period III,
Time, months CaCO3 (seven months).
500 -
E
=C
E2 60
C,
E
C,(I)
40
20
0
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300
" 200 —
100
Al(OH)3 3 Month 7
I I
CaCO3
0
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CaCO3
Fig. 4. The effect of replacing Al(OH)3 with CaCO3 on serum PTH.
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though serum aluminum is not a perfect indicator of the total
body burden of aluminum, these studies indicate that cessation
of ingestion of aluminum binders leads to a decrease of serum
aluminum concentrations toward normal. However, we cannot
predict from the current studies, the period of time necessary
for the total amount of aluminum retained in the body to be
eliminated via dialysis without the use of desferoxamine. Nev-
ertheless, the results are encouraging. If patients are asympto-
matic and not further exposed to aluminum, they will probably
not experience the deleterious effect of aluminum intoxication.
Since the concentration of calcium in the dialysate was
decreased from 3.25 to 2.5 mEq/liter, secondary hyperparathy-
roidism could potentially be aggravated. Johnson [32] reported
an increase in PTH levels when dialysate calcium was reduced
below 3 mEq/liter. In our studies, parathyroid hormone did not
increase. In similar studies, Sawyer et al [30] found a marked
decrease in the levels of parathyroid hormone from 241 to 116
pglml. Our results are similar to the ones obtained by Mactier
and collaborators [29] in which the levels of PTH did not change
significantly. It is important to emphasize that patients main-
tained on a 2.5 mEqlliter calcium bath will develop severe
secondary hyperparathyroidism with the administration of
small amounts of calcium carbonate. Therefore, the use of
dialysate formulated in this manner should probably be re-
stricted to those patients who demonstrate good compliance. In
addition, it is important to ensure that the patients ingest a form
of CaCO3 with adequate dissolution rates. Under these circum-
stances, the ingestion of large amounts of calcium carbonate
compensates for the decrement in the amount of calcium in the
dialysate and the levels of parathyroid hormone do not in-
crease. Since it is well known that the set point for calcium in
the suppression of parathyroid hormone secretion is abnormal
in patients with chronic renal failure [33], attempts should be
made to maintain serum calcium in the upper limits of normal.
We strongly recommend that dietitians determine the total
amount of phosphorus ingested during 24 hours and during each
meal. There is both patient to patient variability, and variability
from meal to meal in the same patient. Thus, to prevent the
development of hypercalcemia, it is important to prescribe
CaCO3 according to the amount of phosphorus ingested in a
given meal. The dose of calcium carbonate administered with
each meal should be adjusted to match the phosphorus intake at
that time. Mismatching of the phosphate ingestion and the
amount of phosphate binder may lead to inadequate phosphate
control on the one hand and hypercalcemia on the other. As
phosphate absorption from the gastrointestinal tract is fairly
rapid, the ability of CaCO3 to bind phosphate is greatest if the
binder is given with the meal. Recently Schiller and collabora-
tors [34] demonstrated, during strict phosphate gastrointestinal
balance studies, that the binding of dietary phosphorus is
quantitively more important than binding of endogenous phos-
phorus. In addition, they also found that the administration of
calcium acetate was more effective in binding phosphorus when
given immediately before or after a meal. If the binder was
given two hours after the meal, a substantially greater amount
of phosphorus is absorbed. In our study, the amount of calcium
carbonate prescribed correlated well with the amount of phos-
phorus ingested (Fig. 1).
Some physicians have expressed concern regarding the de-
velopment of hypotension during dialysis with a low calcium
dialysate bath. There is an apparent increase in cardiac function
when patients are dialyzed with a dialysate high in calcium [35].
Although the blood pressure may fall if patients are dialyzed
with 2.5 mEq/liter of calcium in the dialysate, the severity is
clinically minor (<5 to 9 mm Hg) [36—38].
Although we have found that serum phosphorus can be
controlled in all 21 patients without the administration of
aluminum hydroxide, we believe that, if the serum calcium
reaches a concentration of 11 mgldl, the amount of CaCO3 given
should not be increased further. In those few patients in which
hyperphosphatemia persists, the patient should receive phos-
phate binders containing Al. Larger amounts of calcium car-
bonate will probably induce severe hypercalcemia and increase
the associated risk of extraskeletal calcification. It is important
to emphasize that although dietary phosphate plays the most
important role in phosphate balance in patients with severe
secondary hyperparathyroidism, the serum phosphorus may
reflect not only dietary phosphorus, but also the efflux of
phosphorus from the skeleton due to the action of parathyroid
hormone. Obviously, in these patients phosphate binders will
not significantly change the levels of serum phosphorus. They
are potential candidates for surgical parathyroidectomy.
Recently, new modalities are being tested in the treatment of
hyperphosphatemia and secondary hyperparathyroidism. Sheikh
and collaborators [39] demonstrated that calcium acetate may bind
phosphorus more efficiently than calcium carbonate or calcium
citrate. These investigators found that calcium acetate bound 1.04
0.1 mg of phosphorus per mg of calcium absorbed. This was
significantly better than calcium carbonate (0.57 0.5) and
calcium citrate (0.43 0.07). If these results are confirmed by
other investigators, calcium acetate may prove to be a clinically
useful phosphate binder.
Concomitant treatment of secondary hyperparathyroidism
with 1 ,25(OH)2D3 and large amounts of calcium carbonate can
be associated with hypercalcemia. A new analog of calcitriol,
22-OXA, 1 ,25(OH)2D3[OXACALCITRIOL (OCT)] is devoid of
a calcemic effect in experimental animals, yet has a similar
suppressive effect on PTH synthesis and release as 1,25
(OH)2D3 [40]. Potentially this compound could be administered
with large amounts of calcium carbonate without the attendant
risk of inducing severe hypercalcemia. Further studies are
necessary to fully evaluate all the metabolic effects of this new
analog of vitamin D.
In summary, calcium carbonate is an effective phosphate
binder. Lowering dialysate calcium to 2.5 mEq/liter allowed the
long-term administration of large doses of calcium carbonate.
This corrected the hyperphosphatemia without the develop-
ment of hypercalcemia or worsening of secondary hyperpara-
thyroidism. Aluminum levels returned toward normal. Thus, by
utilizing this maneuver, aluminum binders may be unnecessary
in the majority of patients on maintenance hemodialysis.
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